FDA CBER Document

Presented to FDA 10/22/2020

Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation

CBER Plans for Monitoring COVID-19 Vaccine Safety and Effectiveness

NOTE:
– page 2 – TITLE
Рslide 8 РPOST licensure safety surveillance Рthis way they do not have to report pre-licensure and this is why no licensed products have been approved
– Slide 11 – BEST System (no publicly available data to this point)
– page 16 – CMS data and near real time efforts
– page 17 – Adverse events outcomes being monitored for
– page 23-24 – Govt agencies monitoring safety and weekly meetings – they knew

Share now!

You cannot copy content of this page